spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ascites 

 HSMN NewsFeed - 12 Feb 2024
AbbVie Completes Acquisition of ImmunoGen
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Apr 2022
Bearpac Medical Announces Exclusive UK Distribution Agreement with APR Medtech Ltd for the Passio(TM) Pump Drainage System
Devices Distribution
 HSMN NewsFeed - 5 Apr 2022
Bearpac Medical Announces CE Mark Certification for the Passio(TM) Pump Drainage System
Devices Regulatory
 HSMN NewsFeed - 23 Jun 2021
BD Announces Expanded 510(k) Clearance for At-Home System for Ascites
Devices FDA
 HSMN NewsFeed - 13 Dec 2019
Clinical Data from Reprieve Cardiovascular's Successful First-in-Human Therapy for Acute Heart Failure Presented
Devices Cardiology
 HSMN NewsFeed - 15 Aug 2019
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Biopharmaceuticals
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Apr 2019
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress(TM) (EASL)
Biopharmaceuticals
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2018
Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with SyntArray, LLC
Biopharmaceuticals Personalized Medicine Licensing
 HSMN NewsFeed - 24 Oct 2017
Sequana Medical Announces Results of the MOSAIC Trial Data Presented at 2017 AASLD
Devices
 HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2017
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
Devices Oncology
 HSMN NewsFeed - 15 Mar 2017
Julie G. Anderson Joins BioVie as Independent Director and Investor
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2016
Sequana Medical Announces Sudden Passing of Founder, President & CEO; Ian Crosbie Appointed Chief Executive Officer
Devices Personnel
 HSMN NewsFeed - 14 Oct 2016
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva(R) (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Sep 2016
BioVie's Lead Compound BIV201 Receives FDA Orphan-Drug Designation for the Treatment of Ascites
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Oct 2015
Sequana Medical AG Raises CHF 9 million (USD 9.3M) in a Series C Extension
Devices Venture Capital
 HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Apr 2015
Sequana Medical signs collaboration agreement with Fresenius Medical Care for the marketing and distribution of the alfapump(R) system
Devices Distribution
 HSMN NewsFeed - 6 Apr 2015
FDA Expands Indication for EVARREST(R) Fibrin Sealant Patch
Devices Surgery FDA
 HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Sep 2013
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
Diagnostics Personnel
 HSMN NewsFeed - 30 Oct 2012
Sequana Medical Receives CE-Mark Approval for the use of its alfapump(R) System in Cancer Patients With Malignant ascites
Devices Oncology Regulatory
 HSMN NewsFeed - 20 Apr 2012
Sequana Medical’s ALFApump(R) System Proves to Be a Safe and Efficacious Breakthrough Technology in Ascites Management
Devices
 HSMN NewsFeed - 1 Mar 2012
Sequana Medical's ALFApump(R) System Receives Reimbursement in Germany for Breakthrough Technology in Ascites Management
Devices Regulatory Reimbursement
 HSMN NewsFeed - 4 Nov 2011
The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump(R) System
Devices
 HSMN NewsFeed - 13 Jul 2011
Sequana Medical Receives CE Mark Approval for the ALFApump System and Adds Key Executive to Team
Devices Personnel
 HSMN NewsFeed - 30 May 2011
NovaShunt Announces the Launch of its New Corporate Identity: Sequana Medical
Devices
 HSMN NewsFeed - 25 Apr 2011
First Patient Enrolled in Gore Early TIPS for Ascites Study at Indiana University Hospital
Devices
 HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab(R)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 18 Oct 2010
U.S. Food and Drug Administration Approves BARACLUDE(R) (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2010
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2010
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of Non-Constipation Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2010
NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
Devices
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2009
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
Biopharmaceuticals
 HSMN NewsFeed - 1 Apr 2009
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2008
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2008
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Nov 2007
The Aethlon Hemopurifier(R) Reverses Immune Suppression in Cancer
Devices Oncology
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 25 Oct 2007
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2007
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2007
Salix Pharmaceuticals Licenses OSMOPREP(TM) To Mayoly-Spindler in France
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 25 Sep 2007
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Sep 2007
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2007
Secondary Endpoints of Phase II/III Study Confirm Clear Benefits from Treatment With removab(R) for Patients with Malignant Ascites
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2007
Salix Pharmaceuticals Announces Imminent Launch of Visiclear(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Mar 2007
FDA Approves Astellas' Vaprisol(R) for the Treatment of Hypervolemic Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2007
ELAD(R) Bioartificial Liver Trial in China Achieves Significance at Halfway Point
Devices
 HSMN NewsFeed - 13 Dec 2006
OSMOPREP(TM) Tablets Granted MHRA Marketing Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Dec 2006
Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2006
New Data on Otsuka's Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Oct 2006
Valeant Pharmaceuticals Presents End-of-Treatment Results of DIRECT Trial for Infergen at the American Association for the Study of Liver Diseases 2006 Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
Salix Pharmaceuticals Reports American College of Gastroenterology Update
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Oct 2006
Lilly Launches Phase III 'GALES' Trial of ALIMTA(R) (Pemetrexed for Injection) in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Cardinal Health Completes Acquisition of Denver Biomedical, a Manufacturer of Specialized Medical Devices
Devices Mergers & Acquisitions
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
ascites
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.